Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/20/20
End: 05/19/25
Due: 05/19/26
Phase: N/A
Priority: Normal
Start: 03/06/24
End: 08/31/26
Due: 08/31/27
Phase: N/A
Priority: Normal
Start: 10/01/19
End: 12/31/20
Due: 12/31/21
Phase: N/A
Priority: Normal
Start: 11/30/15
End: 08/20/21
Due: 08/20/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Sulindac and Breast Density in Women at Risk of Developing Breast Cancer | NCT04542135 | Alison Stopeck | user2@example.com | None | 2020-11-20 | 2025-05-19 | 2026-05-19 | - | - | 2025-07-14 |
| Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer | NCT06220214 | Alison Stopeck | user2@example.com | None | 2024-03-06 | 2026-08-31 | 2027-08-31 | - | - | 2025-07-14 |
| Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer | NCT04088032 | Alison Stopeck | user2@example.com | None | 2019-10-01 | 2020-12-31 | 2021-12-31 | - | - | 2025-07-14 |
| Denosumab and MRI Breast Imaging | NCT02613416 | Alison Stopeck | user2@example.com | None | 2015-11-30 | 2021-08-20 | 2022-08-20 | - | - | 2025-07-14 |